CAAS Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

CAAS Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,000	Closed	-$1.26M	–	885
2021 Q4	$1.26M	Hold	2,000	–	–	0.03%	400
2021 Q3	$1.21M	Hold	2,000	–	–	0.02%	446
2021 Q2	$1.12M	Hold	2,000	–	–	0.02%	520
2021 Q1	$946K	Sell	2,000 -300	-13%	-$146K	0.01%	818
2020 Q4	$1.11M	Buy	2,300 +2,000	+667%	+$1.08M	0.01%	594
2020 Q3	$168K	Hold	300	–	–	﹤0.01%	447
2020 Q2	$187K	Sell	300 -3,000	-91%	-$1.7M	0.01%	369
2020 Q1	$1.61M	Buy	+3,300	New	+$1.36M	0.17%	107

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAAS Capital Management's REGN Position: Q1 2022 in Review

CAAS Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 994 shares — an estimated $628K sold.

CAAS Capital Management first reported a position in REGN in Q2 2020 and held it in 6 quarters. The position peaked at $2.14M in Q1 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

CAAS Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
CAAS Capital Management sold 994 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $628K.
CAAS Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 6 quarters.
CAAS Capital Management's Regeneron Pharmaceuticals position peaked at $2.14M in Q1 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.